MGC Diagnostics Corporation Appoints Wesley W. Winnekins as Executive Vice
President, Finance and Corporate Development; Winnekins will also serve as
Chief Financial Officer
SAINT PAUL, Minn., Feb. 4, 2013
SAINT PAUL, Minn., Feb. 4, 2013 /PRNewswire/ -- MGC Diagnostics Corporation
(NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology
company, today announced the appointment of Wesley W. Winnekins as Executive
Vice President, Finance and Corporate Development, effective immediately. Mr.
Winnekins will also serve as the Company's Chief Financial Officer.
In connection with the appointment of Mr. Winnekins, the Company will be
entering into a Separation Agreement with the prior Chief Financial Officer
Robert M. Wolf. Mr. Wolf's last day as Chief Financial Officer was January
Prior to joining MGC Diagnostics, Mr. Winnekins served as Chief Financial
Officer of Snap Fitness, Inc.a multi-national franchisor of 24/7 express
fitness clubs from February 2011 to October 2012. Prior to that, he was
employed by Health Fitness Corporation from February 2001 to December 2010,
serving as Executive Vice President, Finance and Operations from March 2010 to
December 2010, and as Chief Financial Officer and Treasurer from February 2001
to February 2010. Prior to working at Health Fitness Corporation, Mr.
Winnekins served in finance and management capacities for several public and
private companies, including health and fitness companies, from October 1987
to February 2001. From May1985 to October1987, Mr. Winnekins served in the
audit practice at Arthur Andersen. Mr.Winnekins received a Bachelor's in
Business Administration with a major in Accounting from Iowa State University
and has passed the CPA exam.
Gregg O. Lehman, Ph.D., president and chief executive officer of MGC
Diagnostics, said, "I am pleased to have Wes Winnekins join our management
team. He is a proven public company financial executive with a broad skill set
that includes SEC financial reporting, mergers and acquisitions, and a highly
developed network of professionals that spans a career of more than 25 years.
These credentials will make Wes an invaluable partner as we continue to
execute our strategic plan."
"I want to express my appreciation to Rob Wolf who has left the Company to
pursue other opportunities," continued Dr. Lehman. "Rob has been a valuable
member of our leadership team and has provided stability and solid performance
during his tenure as CFO. I am grateful for his contributions and wish him
the best in the future."
About MGC Diagnostics
MGC Diagnostics Corporation (NASDAQ: MGCD), (formerly Angeion Corporation), is
a global medical technology company dedicated to cardiorespiratory health
solutions. MGC Diagnostics develops, manufactures and markets non-invasive
diagnostic systems. This portfolio of products provide solutions for disease
detection, integrated care, and wellness across the spectrum of
cardiorespiratory healthcare. The Company's products are sold internationally
through distributors and in the United States through a direct sales force
targeting heart and lung specialists located in hospitals, university-based
medical centers, medical clinics, physicians' offices, pharmaceutical
companies, medical device manufacturers, and clinical research organizations
(CROs). For more information about MGC Diagnostics, visit
Cautionary Statement Regarding Forward Looking Statements
From time to time, in reports filed with the Securities and Exchange
Commission, in press releases, and in other communications to shareholders or
the investing public, MGC Diagnostics Corporation may make forward−looking
statements concerning possible or anticipated future financial performance,
business activities or plans that include the words "believes," "expects,"
"anticipates," "intends" or similar expressions. For these forward−looking
statements, the Company claims the protection of the safe harbor for
forward−looking statements contained in federal securities laws. These
forward−looking statements are subject to a number of factors, risks and
uncertainties, including those disclosed in our periodic filings with the SEC,
that could cause actual performance, activities or plans after the date the
statements are made to differ significantly from those indicated in the
forward−looking statements. For a list of these factors¸ see the sections
entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking
Statements," in the Company's Form 10-K for the year ended October 31, 2012,
and any updates in subsequent filings on Form 10-Q or Form 8-K under the
Securities Exchange Act of 1934.
Contact: Gregg O. Lehman, Ph.D. Joe Dorame, Robert Blum, Joe Diaz
MGC Diagnostics Corporation Lytham Partners, LLC
Chief Executive Officer (602) 889-9700
(651) 484-4874 firstname.lastname@example.org
SOURCE MGC Diagnostics Corporation
Press spacebar to pause and continue. Press esc to stop.